Drugs / Cobalamin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03790345 | Sep 2019 → Jun 2020 | movement disorder, schizophrenia | Drug Research and Development Center, Federal University of Ceara | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01476007 | Jul 2014 → Nov 2017 | vitamin B12 deficiency | Gerencia de Atención Primaria, Madrid | Completed | Mixed |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05096663 Background | Mar 2022 → Jun 2027 expected | non-small cell lung carcinoma | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cobalamin | “Cobalamin” NCT05096663 ↗ |
| Modality | Small molecule | — CHEMBL4297272 ↗ |
| Route | Oral | “Intervention group: oral Optovite® B12 1000 gammas.” NCT01476007 ↗ |